Global Autoimmune Hemolytic Anemia Treatment Market By Type (Warm Autoimmune Induced Hemolytic Anemia, Cold Agglutinin Disease (CAD) and Others), Therapy Type (First Line Therapy, Second Line Therapy, Third Line Therapy), Drugs (Steroid Therapy, Immunosuppressive Agents and Others), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2026
Market Analysis: Global Autoimmune Hemolytic Anemia Treatment Market
Global Autoimmune hemolytic anemia Treatment Market is growing at a steady CAGR in the forecast period of 2019-2026. Increasing research and development expenses and high demand of novel therapies are some factors fueling the market growth
Market Definition: Global Autoimmune Hemolytic Anemia Treatment Market
Autoimmune Hemolytic Anemia is also known as idiopathic autoimmune hemolytic is defined as rare, autoimmune disorders in which various types of auto-antibodies are directed against red blood cells. It occurs when immune system dysfunction and start produces auto-antibodies, which destroy red blood cells at faster rate before there life span over. Destruction of red blood cells results in severe complications including anemia, leading to weakness and fatigue.
According to the statistics published in the Orphanet,an estimated annual incidence of autoimmune hemolytic anemia is 1 in 35,000-80,000 in the North America and Western Europe. Huge financial support from the government and increase demand of novel treatment are key factors for market growth
- The emergence of drugs such as penicillin, antimalarial medicines, sulfa medicines and acetaminophen for treating chronic conditions as these drugs can induce hemolytic anemia is act as drivers for market growth
- Prevalence of certain tumors and autoimmune disorders can increase the risk of hemolytic anemia is accelerating the market growth
- Huge financial support to the researchers for developing novel intervention is enhancing the market growth
- High specific demand of novel treatment is propelling the market growth
- Lack of trained personnel and stringent safety regulations is hampering the market growth
- Limited availability of specific medicinal treatment options due to low prevalence of hemolytic anemia is restraining the market growth
Segmentation: Global Autoimmune Hemolytic Anemia Treatment Market
- Warm Autoimmune Induced Hemolytic Anemia
- Cold Agglutinin Disease (CAD)
By Therapy Type
- First Line Therapy
- Second Line Therapy
- Third Line Therapy
- Steroid Therapy
- Immunosuppressive Agents
By Route of Administration
By End Users
- Specialty Clinics
- North America
- South America
- Rest of South America
- United Kingdom
- Rest of Europe
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- South Africa
- Rest of Middle East & Africa
Key Developments in the Market:
In August 2019, Momenta Pharmaceuticals, Inc initiated phase II/III trial for Nipocalimab (M281), an FcRn inhibitor to be developed for the treatment of warm Autoimmune Hemolytic Anemia (wAIHA). It is also received Fast Tract designation from the FDA for Nipocalimab. The Fast Track designation accelerates review timelines and enhances the interaction with the FDA, which can bring drug to the patients as quickly as possible.
In June 2019, Apellis Pharmaceuticals presented a data for its phase II (PLAUDIT study) of APL-2 at the 24th Annual Congress of the European Hematology Association (EHA), the Netherlands. The trial has demonstrated improvements in hematologic measures in patients with utoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Seeing the potential promising results of their upcoming novel C3 inhibitor will help the patients with autoimmune hemolytic anemia throughout the world.
Global autoimmune hemolytic anemia treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Global autoimmune hemolytic anemia treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Key Market Players:
Few of the major competitors currently working in the autoimmune hemolytic anemia treatment market are Momenta Pharmaceuticals, Inc, Apellis Pharmaceuticals, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Zydus Cadila, Vertice Pharma, Concord Biotech, Alkem Labs, Dr. Reddy’s Laboratories Ltd, Jubilant Life Sciences Ltd, Strides Pharma Science Limited, Mylan N.V., Novartis AG, Sanofi, Rigel Pharmaceuticals Inc, Incyte Corporation, Alexion Pharmaceuticals, Inc and others
Research Methodology: Global Autoimmune Hemolytic Anemia Treatment Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.
Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
Reasons to Purchase this Report
- Current and future of global autoimmune hemolytic anemia treatment market outlook in the developed and emerging markets
- The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
- Regions/Countries that are expected to witness the fastest growth rates during the forecast period
- The latest developments, market shares, and strategies that are employed by the major market players